Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pfizer, Inc. Deutsche Boerse AG

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 14:48:29 2024-05-17 EDT 		5-day change 1st Jan Change
26.3 EUR -1.22% Intraday chart for Pfizer, Inc. +0.79% +0.75%
05-17 Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial RE
05-17 Sector Update: Health Care Stocks Mixed Late Afternoon MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 216,827 204,605 331,440 287,626 162,560 162,291 - -
Enterprise Value (EV) 1 259,147 232,220 338,807 300,723 221,758 220,403 212,256 205,901
P/E ratio 13.7 x 21.5 x 15.3 x 9.37 x 77.8 x 19.9 x 14 x 13 x
Yield 3.68% 4.13% 2.64% 3.14% 5.73% 5.83% 5.94% 6.06%
Capitalization / Revenue 4.19 x 4.88 x 4.08 x 2.87 x 2.78 x 2.69 x 2.59 x 2.56 x
EV / Revenue 5.01 x 5.54 x 4.17 x 3 x 3.79 x 3.65 x 3.38 x 3.25 x
EV / EBITDA 12.3 x 13 x 13.3 x 7.1 x 14.2 x 10.4 x 8.92 x 8.27 x
EV / FCF 24.9 x 19.1 x 11.3 x 11.6 x 46.3 x 22.1 x 14.5 x 12.7 x
FCF Yield 4.02% 5.23% 8.82% 8.66% 2.16% 4.52% 6.91% 7.86%
Price to Book 3.43 x 3.24 x 4.3 x 3 x 1.83 x 1.85 x 1.86 x 1.83 x
Nbr of stocks (in thousands) 5,534,122 5,558,397 5,612,867 5,613,315 5,646,413 5,666,593 - -
Reference price 2 39.18 36.81 59.05 51.24 28.79 28.64 28.64 28.64
Announcement Date 20-01-28 21-02-02 22-02-08 23-01-31 24-01-30 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 51,750 41,908 81,288 100,330 58,496 60,407 62,707 63,352
EBITDA 1 21,097 17,801 25,426 42,336 15,590 21,189 23,783 24,910
EBIT 1 19,420 13,024 20,235 37,272 9,300 17,050 19,102 20,254
Operating Margin 37.53% 31.08% 24.89% 37.15% 15.9% 28.23% 30.46% 31.97%
Earnings before Tax (EBT) 1 17,682 7,497 24,311 34,729 1,058 11,020 14,826 13,713
Net income 1 16,273 9,616 21,979 31,372 2,119 7,775 11,288 11,733
Net margin 31.45% 22.95% 27.04% 31.27% 3.62% 12.87% 18% 18.52%
EPS 2 2.870 1.710 3.850 5.470 0.3700 1.438 2.049 2.202
Free Cash Flow 1 10,412 12,151 29,869 26,031 4,793 9,957 14,672 16,181
FCF margin 20.12% 28.99% 36.74% 25.95% 8.19% 16.48% 23.4% 25.54%
FCF Conversion (EBITDA) 49.35% 68.26% 117.47% 61.49% 30.74% 46.99% 61.69% 64.96%
FCF Conversion (Net income) 63.98% 126.36% 135.9% 82.98% 226.19% 128.05% 129.98% 137.92%
Dividend per Share 2 1.440 1.520 1.560 1.610 1.650 1.671 1.701 1.737
Announcement Date 20-01-28 21-02-02 22-02-08 23-01-31 24-01-30 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 23,838 25,661 27,742 22,638 24,290 18,282 12,734 13,232 14,249 14,879 13,050 14,847 17,770 15,680 13,725
EBITDA 1 4,403 11,135 13,583 10,325 6,772 7,857 4,925 -1,244 1,340 - 3,758 4,680 4,537 - -
EBIT 1 3,126 9,948 12,408 9,142 5,253 6,370 3,319 -1,625 -330 5,912 3,423 3,804 3,977 - -
Operating Margin 13.11% 38.77% 44.73% 40.38% 21.63% 34.84% 26.06% -12.28% -2.32% 39.73% 26.23% 25.62% 22.38% - -
Earnings before Tax (EBT) 1 - 9,050 - - 5,231 - - -3,352 -4,129 3,421 1,962 2,926 3,380 - -
Net income 1 3,393 7,864 9,906 8,608 4,995 5,543 2,327 -2,382 -3,369 3,115 1,496 2,046 2,679 - -
Net margin 14.23% 30.65% 35.71% 38.02% 20.56% 30.32% 18.27% -18% -23.64% 20.94% 11.46% 13.78% 15.08% - -
EPS 2 0.5900 1.370 1.730 1.510 0.8700 0.9700 0.4100 -0.4200 -0.6000 0.5500 0.2472 0.3622 0.4697 - -
Dividend per Share 2 0.3900 0.4000 0.4000 0.4000 0.4100 0.4100 0.4100 0.4100 0.4200 0.4200 0.4159 0.4159 0.4159 0.4220 0.4220
Announcement Date 22-02-08 22-05-03 22-07-28 22-11-01 23-01-31 23-05-02 23-08-01 23-10-31 24-01-30 24-05-01 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 42,320 27,615 7,367 13,097 59,198 58,112 49,965 43,610
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.006 x 1.551 x 0.2897 x 0.3094 x 3.797 x 2.743 x 2.101 x 1.751 x
Free Cash Flow 1 10,412 12,151 29,869 26,031 4,793 9,957 14,672 16,181
ROE (net income / shareholders' equity) 25.7% 15.2% 31.3% 43.5% 11.4% 14% 16.6% 17%
ROA (Net income/ Total Assets) 9.96% 5.98% 13.1% 19.9% 4.96% 4.59% 5.8% 6.44%
Assets 1 163,456 160,910 167,853 157,490 42,750 169,492 194,570 182,069
Book Value Per Share 2 11.40 11.40 13.70 17.10 15.80 15.50 15.40 15.70
Cash Flow per Share 2 2.220 2.560 5.710 5.110 1.520 2.920 3.320 3.260
Capex 1 2,176 2,252 2,711 3,236 3,907 2,783 2,894 2,914
Capex / Sales 4.2% 5.37% 3.34% 3.23% 6.68% 4.61% 4.61% 4.6%
Announcement Date 20-01-28 21-02-02 22-02-08 23-01-31 24-01-30 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Pfizer, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.64 USD
Average target price
31.94 USD
Spread / Average Target
+11.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
NOVARTIS AG Stock Novartis AG
+10.02% 209B
AMGEN INC. Stock Amgen Inc.
+8.49% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. PFE Stock
  5. Financials Pfizer, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW